Trial reportDrug and alcohol dependence2014
Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy.
Trial report in Drug and alcohol dependence, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Maintenance agonist treatments for opiate-dependent pregnant women.The Cochrane database of systematic reviews · 2020Pooled it
- Is buprenorphine maternal dose associated with neonatal opioid withdrawal syndrome severity?The American journal on addictions · 2025Article
- Maternal opioid use during pregnancy and the risk of neonatal opioid withdrawal syndrome in the offspring.Acta obstetricia et gynecologica Scandinavica · 2024Article
- Development and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear Bioavailability.Drug metabolism and disposition: the biological fate of chemicals · 2024Article
- Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome.Drug and alcohol dependence · 2023Article
- Article
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats.Frontiers in pharmacology · 2023Article
- Informing the Development of a Standardized Clinical Definition of Neonatal Abstinence Syndrome: Protocol for a Modified-Delphi Expert Panel.JMIR research protocols · 2021Article
- Human Fetal Liver Metabolism of Oxycodone Is Mediated by CYP3A7.The AAPS journal · 2021Article
- In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome.The Journal of pharmacology and experimental therapeutics · 2019Article
- Maternal buprenorphine treatment and infant outcome.Drug and alcohol dependence · 2017Article
- Buprenorphine for Medication-Assisted Treatment of Opioid Use Disorder in Pregnancy: Relationship to Neonatal Opioid Withdrawal Syndrome.AJP reports · 2017Article
- An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy.American journal of obstetrics and gynecology · 2017Article
- Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.Drug safety · 2016Review
- Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant.Seminars in perinatology · 2016Review
- Review
- Prescription opioid epidemic and infant outcomes.Pediatrics · 2015Article
- Infant neurodevelopmental outcomes of prenatal opioid exposure and polysubstance use.Neurotoxicology and teratologyArticle
- Co-occurrence of preconception maternal childhood adversity and opioid use during pregnancy: Implications for offspring brain development.Neurotoxicology and teratologyArticle
- Treating Women Who Are Pregnant and Parenting for Opioid Use Disorder and the Concurrent Care of Their Infants and Children: Literature Review to Support National Guidance.Journal of addiction medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundBuprenorphine pharmacotherapy for opioid-dependent pregnant women is associated with maternal and neonatal outcomes superior to untreated opioid dependence. However, the literature is inconsistent regarding the possible existence of a dose-response relationship between maternal buprenorphine dose and neonatal clinical outcomes.
methodsThe present secondary analysis study (1) examined the relationship between maternal buprenorphine dose at delivery and neonatal abstinence syndrome (NAS) peak score, estimated gestational age at delivery, Apgar scores at 1 and 5 min, neonatal head circumference, length, and weight at birth, amount of morphine needed to treat NAS, duration of NAS treatment, and duration of neonatal hospital stay and (2) compared neonates who required pharmacotherapy for NAS to neonates who did not require such pharmacotherapy on these same outcomes, in 58 opioid-dependent pregnant women receiving buprenorphine as participants in a randomized clinical trial.
results(1) Analyses failed to provide evidence of a relationship between maternal buprenorphine dose at delivery and any of the 10 outcomes (all p-values>.48) and (2) significant mean differences between the untreated (n=31) and treated (n=27) for NAS groups were found for duration of neonatal hospital stay and NAS peak score (both p-values<.001).
conclusions(1) Findings failed to support the existence of a dose-response relationship between maternal buprenorphine dose at delivery and any of 10 neonatal clinical outcomes, including NAS severity and (2) that infants treated for NAS had a higher mean NAS peak score and, spent a longer time in the hospital than did the group not treated for NAS is unsurprising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.